A股異動 | 迪安診斷(300244.SZ)大漲超8% Q3業績環比有較大提升
格隆匯10月25日丨迪安診斷(300244.SZ)快速拉昇漲超8%,報32.84元,總市值超200億元。公司22日晚公吿,第三季度主營收入35.47億元,同比上升18.27%;歸母淨利潤5.06億元,同比上升27.05%。環比二季度有較大提升,主要是國內三季度多地散發疫情帶來新冠檢測量提升,剔除新冠業務,常規ICL服務和產品業務預計延續了上半年的恢復增長態勢。中泰證券點評稱,公司業績符合預期,常規ICL服務+產品持續恢復。考慮到公司實驗室經營趨勢向好,自產產品加速放量,綜合服務競爭能力持續提升,維持“買入”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.